Cavicchi C, Chilleri C, Fioravanti A, Ferri L, Ripandelli F, Costa C, Calabresi P, Prontera P, Pochiero F, Pasquini E, Funghini S, la Marca G, Donati MA, Morrone A
During concurrent use , patients should contact their healthcare provider if they experience: Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) Severe, persistent abdominal pain (often radiating to the back) with or without vomitingthis could indicate pancreatitis, a serious adverse effect associated with GLP-1 receptor agonists requiring urgent medical evaluation Unexplained fatigue, jaundice, or abdominal pain (potential liver concerns) Worsening gastrointestinal symptoms beyond typical semaglutide side effects New or unusual symptoms that may represent an adverse reaction Patients taking oral medications with a narrow therapeutic index should discuss timing and monitoring with their healthcare provider, as semaglutide's effect on gastric emptying may affect absorption

Therefore, in initial pilot clinical studies (Figure 1), we first explored (in omnivores) whether BB could be formed from l-carnitine following oral ingestion of heavy isotopelabeled l-carnitine (d 3 -l-carnitine), and the potential participation of gut microbiota in that reaction
30 , e13196 (2018)